Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-01 · accession 0000950170-25-032802 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-04 | 2025-03-03 | RARE | Kassberg Thomas Richard | EVP, CBO | F - Tax | $42.92 | -508 | 264.7K | -0.2% | -$21.8K | |
| 2025-03-04 | 2025-03-01 | RARE | Kassberg Thomas Richard | EVP, CBO | A - Grant | $0.00 | +18.4K | 271.3K | +7% | $0 | |
| 2025-03-04 | 2025-03-03 | RARE | Kassberg Thomas Richard | EVP, CBO | S - Sale | $42.10 | -6,028 | 265.2K | -2% | -$253.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | F | D | 508 | $42.92 | 264,730 | D | — | — | (F4) Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. (F5) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| 2 | Common | Common Stock | 2025-03-01 | A | A | 18,443 | $0.00 | 271,266 | D | — | — | (F1) Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. |
| 3 | Common | Common Stock | 2025-03-03 | S | D | 6,028 | $42.10 | 265,238 | D | — | — | (F2) Represents shares sold to pay required tax withholdings due to the vesting of RSUs. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |